Issue 02

REGULATION AND LEGISLATION


An attempt to block the Washington D.C. psychedelics initiative fails.


Psychedelic therapists request approval to test use psychedelics themselves in Canada.


UK’s Medical Psychedelics Working Group launches rescheduling campaign.


Oregon will vote on the legalisation of psilocybin for therapeutic use in November 2020.

BUSINESS AND INVESTMENT


Clarmin to acquire psychedelics firm Cybin in reverse takeover.


Core One Labs completes acquisition of interest in Rejuva and Shahcor medical clinics.


ATAI Life Sciences acquires Kures to develop novel therapeutics for opioid abuse.


Mydecine Innovations signs definitive agreement to acquire Neuropharm.


MagicMed Industries files provisional patent for psilocybin derivatives.


PharmaDrug completes the share exchange transaction with Red Light Holland.


Novamind closes private funding round at CA$4.4 million.

RESEARCH AND SCIENCE


Mydecine Innovations commences PTSD clinical trial initiative with Leiden University.


New study suggests that spiritual or psychological insight drive psilocybin popularity.


LSD use among US adults increased by 56% from 2015 to 2018.


AWAKN Life Sciences forms partnership with Drug Science’s Psychedelics Working Group. 

THE PSYCHEDELICS AS MEDICINE REPORT

Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation.
PSYCH: The Psychedelics as Medicine Report provides unparalleled insights and intelligence from industry experts and market leaders, helping to guide investors, operators and regulators through this transient phase.

FEATURED ARTICLE

The psychedelics industry is championing digital health. Pioneers and early movers in the psychedelics industry are using technology to develop bespoke therapies for patients and to open access to healthcare for greater numbers of patients via telehealth services. Read our analysis here.